From Saturday's edition of Far East Capital's newsletter. I added more as well http://www.fareastcapital.com.au/imagesDB/newsletter/WeeklyComm20November2021copy.pdf
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%